Hasan Khamash, MD
Nephrology · Phoenix, AZNPI 1043219389
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,300 of the $5,682 with a category attached, or 75.7%. 4 manufacturers reported payments, led by Novartis at 58.1% of the total.
Across 6 payments — averaging $946.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Kaneka Medical America LLC$2K
- Sanofi-aventis U.S. LLC$124
- Zimmer Biomet$95
Across 84 payments — averaging $14,999 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1.2M
- E.r. Squibb & Sons, L.L.C.$13K
What the payments were for
- Consulting fees$4,30076%
- Speaking & faculty fees$1,00018%
- Food & beverage$2194%
- Entertainment$1633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $3,300 |
| Kaneka Medical America LLC | 3 | $2,163 |
| Sanofi-aventis U.S. LLC | 1 | $124 |
| Zimmer Biomet | 1 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYMOGLOBULIN$124
How this compares
$5,682 in reported general payments places this provider in the 80th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LokelmaSodium Zirconium Cyclosilicate | 23 | $12,819 |
| Valganciclovir Hcl | 59 | $9,761 |
| Fluconazole | 179 | $6,367 |
| Tacrolimus | 11 | $1,135 |
| Mycophenolate Mofetil | 13 | $1,014 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 89 | $553 |
| Nifedipine ErNifedipine | 14 | $364 |
| Famotidine | 32 | $269 |
| Prednisone | 54 | $262 |
| Carvedilol | 34 | $223 |
| Pantoprazole Sodium | 18 | $118 |
| Atorvastatin Calcium | 18 | $113 |
| Amlodipine Besylate | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Phoenix
- Samer Bani HaniPhoenix$54K
- Leslie ThomasPhoenix$22K
- Alexander NimriPhoenix$21K
- Edgardo LaurelPhoenix$15K
- Sharareh SaadatPhoenix$15K
- Amar BistaPhoenix$12K
- Maher MousaPhoenix$9K
- Paul SacksPhoenix$8K
- William WeissPhoenix$8K
- Esmat MustafaPhoenix$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.